Abstract
Antisense oligodeoxynucleotides (ODNs) inhibit target gene expression and are applicable to human diseases including malignancies. Although improvements in ODNs and cellular delivery systems are needed, antisense ODNs hold great promise as a new class of therapeutic agents.
Get full access to this article
View all access options for this article.
